Low detectable prostate specific antigen after radical prostatectomy--treat or watch?

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• Radical prostatectomy is a primary treatment for prostate cancer.
• Monitoring prostate-specific antigen (PSA) levels post-surgery is crucial for detecting recurrence.
• Predicting biochemical recurrence aids in treatment planning and patient management.

Purpose of the Study:

• To determine if the pattern of low detectable prostate-specific antigen (PSA) in the first three years after radical prostatectomy can predict subsequent biochemical recurrence.
• To identify distinct PSA patterns that correlate with different recurrence risks.

Main Methods:

• A cohort of 566 patients who underwent radical prostatectomy was analyzed.
• Patients were categorized into three groups based on PSA levels and patterns within the first three years: undetectable, low detectable-stable, and low detectable-unstable.
• Biochemical recurrence was defined as PSA ≥ 0.2 ng/ml or receipt of radiation therapy beyond three years.

Main Results:

• Seven-year biochemical recurrence-free survival rates were 95% (undetectable PSA), 94% (low detectable-stable PSA), and 37% (low detectable-unstable PSA).
• PSA pattern (undetectable vs. low detectable-unstable, HR 15.9; undetectable vs. low detectable-stable, HR 1.6) was a significant predictor of recurrence.
• Pathological T stage, Gleason score, and surgical margins also significantly predicted biochemical recurrence.

Conclusions:

• The combination of PSA velocity and National Comprehensive Cancer Network (NCCN) criteria effectively distinguishes between men with low detectable PSA who require treatment and those who can be safely monitored.
• This approach allows for personalized management strategies post-radical prostatectomy based on PSA kinetics.